Fig. 1.

ZNF711 is negatively correlated with CDDP resistance in EOC. (a) Real- time PCR analysis revealed that the level of ZNF711 mRNA was down regulated in EOC cells or tissues compared with the normal ovarian cells; Each bar shown in the figure represents the mean ± SD of three independent experiments. *p < 0.05 (one- way ANOVA followed by Bonferroni's multiple comparisons test). (b) An immuno blotting (IB) assay showed that ZNF711 protein expression was down regulated in EOC cells or tissues compared with the normal ovarian cells. (c) The correlation analysis of the mRNA and protein expression of ZNF711 in EOC cell lines and clinical EOC tissues. (d) An immunohistochemistry (IHC) assay was performed in CDDP-sensitive and CDDP-resistant epithelial ovarian cancer (EOC) tissues using an anti-ZNF711 antibody (200 × , upper; 400 × , lower, Scale bars, 50 μm.). (e) Kaplan-Meier survival analysis of the association of ZNF711 protein expression with overall and relapse-free in EOC patients treated with CDDP. (f) The level of ZNF711 mRNA expression was down regulated in patients with non-CR (partial response, progression and stable) versus CR (complete response) upon CDDP treatment. (g) Kaplan-Meier analysis of the overall and relapse-free survival of the indicated ovarian cancer patients, the cut-off used to define low and high tumors was auto selection of best cut-off.